SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC TO-T - Tender offer statement by Third Party:
SEC Accession No. 0001047469-17-003554
Filing Date
2017-05-23
Accepted
2017-05-22 20:07:29
Documents
5

Document Format Files

Seq Description Document Type Size
1 SC TO-T a2232211zscto-t.htm SC TO-T 33271
2 EX-99.(A)(1)(II) a2232211zex-99_a1ii.htm EX-99.(A)(1)(II) 1549694
3 EX-99.(D)(I) a2232211zex-99_di.htm EX-99.(D)(I) 46376
4 G269086.JPG g269086.jpg GRAPHIC 33092
5 G896674.JPG g896674.jpg GRAPHIC 25393
  Complete submission text file 0001047469-17-003554.txt   1711777
Mailing Address LEBERSTRASSE 20 VIENNA C4 1110
Business Address LEBERSTRASSE 20 VIENNA C4 1110 43 (0)1 740 93-0
Nabriva Therapeutics AG (Subject) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: C4 | Fiscal Year End: 1231
Type: SC TO-T | Act: 34 | File No.: 005-89113 | Film No.: 17862451
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 6108166640
Nabriva Therapeutics Plc (Filed by) CIK: 0001703287 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: SC TO-T
SIC: 2834 Pharmaceutical Preparations